Rain Oncology (RAIN) Stock Forecast, Price & News

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Rain Oncology in the last twelve months. There are currently 10 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" RAIN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RAIN, but not buy additional shares or sell existing shares.
View RAIN analyst ratings or view top-rated stocks.

12 equities research analysts have issued 12 month price targets for Rain Oncology's shares. Their RAIN share price forecasts range from $11.00 to $24.00. On average, they anticipate the company's stock price to reach $17.00 in the next year. This suggests a possible upside of 1,880.0% from the stock's current price.
View analysts price targets for RAIN or view top-rated stocks among Wall Street analysts.

Rain Oncology's stock was trading at $8.00 at the beginning of the year. Since then, RAIN shares have decreased by 89.3% and is now trading at $0.8586.
View the best growth stocks for 2023 here.

Rain Oncology saw a drop in short interest in September. As of September 15th, there was short interest totaling 705,700 shares, a drop of 18.1% from the August 31st total of 861,800 shares. Based on an average daily trading volume, of 302,100 shares, the short-interest ratio is presently 2.3 days. Currently, 3.5% of the shares of the company are sold short.
View Rain Oncology's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our RAIN earnings forecast.

Rain Oncology Inc. (NASDAQ:RAIN) posted its earnings results on Thursday, August, 10th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by $0.12.

ETFs with the largest weight of Rain Oncology (NASDAQ:RAIN) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR), Horizon Kinetics Medical ETF (MEDX),

(RAIN) raised $126 million in an IPO on Friday, April 23rd 2021. The company issued 7,400,000 shares at $16.00-$18.00 per share. Goldman Sachs, Citigroup, Piper Sandler and Guggenheim Securities acted as the underwriters for the IPO.

Rain Oncology trades on the NASDAQ under the ticker symbol "RAIN."

Rain Oncology's stock is owned by a number of retail and institutional investors. Top institutional investors include Samsara BioCapital LLC (5.60%), Boxer Capital LLC (3.17%), BlackRock Inc. (2.80%), Acadian Asset Management LLC (1.81%), Western Standard LLC (0.95%) and Geode Capital Management LLC (0.89%). Insiders that own company stock include Aaron I Davis, Boxer Capital, Llc, Bvf Partners L P/Il, Cormorant Asset Management, Lp, Franklin M Berger, Kevin C Tang, Perceptive Advisors Llc and Value Fund L P Biotechnology.
View institutional ownership trends.

Shares of RAIN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RAIN stock can currently be purchased for approximately $0.86.

Rain Oncology (NASDAQ:RAIN) has a market capitalization of $31.24 million. The company earns $-75,720,000.00 in net income (profit) each year or ($2.55) on an earnings per share basis.

The official website for the company is www.rainthera.com. The company can be reached via phone at 510-953-5559 or via email at bob@lifesciadvisors.com.